Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ginwa Enterprise GroupSHSE:600080 +2.57%46 Current Ratio is 2.00 as of Mar. 2026, which is 38% below its 10-year median of 3.24. GuruFocus rates SHSE:600080 with a GF Score™ of 46/100 and a GF Value™ of ¥7.53 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 995 Drug Manufacturers companies, Ginwa Enterprise Group ranks better than 51.06% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ginwa Enterprise Group's current ratio for the quarter that ended in Mar. 2026 was 2.00.
Ginwa Enterprise Group has a current ratio of 2.00. It generally indicates good short-term financial strength.
The historical rank and industry rank for Ginwa Enterprise Group's Current Ratio or its related term are showing as below:
SHSE:600080'
s Current Ratio Range Over the Past 10 Years
Min: 1.01 Med: 3.24 Max: 5.67
Current: 2
During the past 13 years, Ginwa Enterprise Group's highest Current Ratio was 5.67. The lowest was 1.01. And the median was 3.24.
SHSE:600080's Current Ratio is ranked better than 51.06% of 995
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs SHSE:600080: 2.00
Ginwa Enterprise Group (SHSE:600080) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Ginwa Enterprise Group Current Ratio Related Terms
Ginwa Enterprise Group Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ginwa Enterprise Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginwa Enterprise Group Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ginwa Enterprise Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where Ginwa Enterprise Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginwa Enterprise Group (SHSE:600080) has a Current Ratio of 2.00 as of Mar. 2026. This is 38% below median its historical median of 3.24. Over the past decade, Ginwa Enterprise Group's Current Ratio has ranged from 1.01 to 5.67. According to the industry distribution chart, Ginwa Enterprise Group ranks #487 out of 995 companies in the Drug Manufacturers industry, placing it in the top 48.9%.
Is Ginwa Enterprise Group's Current Ratio too high?
Ginwa Enterprise Group's current Current Ratio of 2.00 is 38% below median its 10-year median of 3.24. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 5.67. The Drug Manufacturers industry median Current Ratio is 1.97. Ginwa Enterprise Group's value of 2.00 is 1.5% above this industry median. Based on the distribution chart, Ginwa Enterprise Group ranks #487 out of 995 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ginwa Enterprise Group has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ginwa Enterprise Group's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ginwa Enterprise Group ranks #487 out of 995 companies for Current Ratio. This puts Ginwa Enterprise Group in the upper half of its industry. The industry median Current Ratio is 1.97. Ginwa Enterprise Group's value of 2.00 is 1.5% above this benchmark. Historically, Ginwa Enterprise Group's own Current Ratio has ranged from 1.01 to 5.67 over the past decade. While the company's 10-year median is 3.24 vs. the industry median of 1.97, Ginwa Enterprise Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.97, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginwa Enterprise Group's current Current Ratio of 2.00 is 1.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginwa Enterprise Group's current Current Ratio is 2.00, which is 38% below median its own 10-year median of 3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginwa Enterprise Group stock overvalued right now?
Based on GuruFocus' analysis, Ginwa Enterprise Group (SHSE:600080) is currently considered Possible Value Trap. The stock's GF Value™ is ¥7.53, compared to a current price of ¥4.79 — trading 36.4% below its estimated fair value. The current Current Ratio is 2.00, which is 38% below median its 10-year median of 3.24 and 1.5% above the Drug Manufacturers industry median of 1.97. Ginwa Enterprise Group's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Ginwa Enterprise Group (SHSE:600080), the current Current Ratio is 2.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginwa Enterprise Group (SHSE:600080) Overvalued in 2026?
Based on GuruFocus' analysis, Ginwa Enterprise Group stock appears to be undervalued.
The current stock price of ¥4.79 is trading 36.4% below its estimated GF Value™ of ¥7.53.
GuruFocus considers Ginwa Enterprise Group to be Possible Value Trap.
Key valuation signals for SHSE:600080:
Current Ratio: 2.00 (38% below median its 10-year median of 3.24)
GF Value™: ¥7.53 vs. price of ¥4.79 (36.4% below fair value)
Industry Position: 1.5% above the Drug Manufacturers median (#487 of 995)
No single metric tells the full story. See the SHSE:600080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginwa Enterprise Group Inc operates in the pharmaceutical industry. The main business is the research and development, production, and sales of drugs, and the product line covers chemical drugs, Chinese patent medicines, raw materials, and health products. The dosage forms include tablets, capsules, granules, powders, mixtures, oral solutions, syrups, external solutions, and more than 100 varieties and specifications.
46GF Score
Get the complete analysis for SHSE:600080
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600080 has been successfully added to your 
